CRISPR Therapeutics AG

CRSPNASDAQ

Market cap5.63B USDAs of Sep 22, 2026

Healthcare· Biotechnology· CH

$58.33

Session change unavailable

Market closed · NASDAQ

Status checked Oct 24, 2026, 11:35 PM · America/New_York

Observed Sep 21, 2026, 8:00 PM UTC · Last available price

CRISPR Therapeutics AG (CRSP)

Loading market observation…

CRISPR Therapeutics AG (CRSP) stock forecast and scoring

Review the dated model forecast and five-factor Scorecard for CRSP. Each has its own availability and reference date; a score is a relative comparison, not a price prediction.

12M forecast summary

Target date · Sep 21, 2027

Lower Estimate (P10)

$31.65

-45.7%

Median Estimate (P50)

$69.63

+19.4% from starting price

Upper Estimate (P90)

$126.82

+117.4%

Median Estimate: $69.63
Starting price: $58.33
Change from starting price: +19.4%
Target date: Sep 21, 2027
Data through: Sep 21, 2026

The estimate uses its dated starting price. It does not predict returns from today’s quote.

View forecast details, dates and available ranges

Stock scorecard

Loading research…

Company Overview

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Similar Stocks

Research snapshot

Loading research…

CRISPR Therapeutics AG research

Loading research…

Model estimates are informational, not investment advice. They are uncertain, may be wrong, and do not guarantee future prices.

Company Overview

Similar Stocks

Explore related companies in our coverage. Open a stock for its full forecast and Scorecard.

Arrowhead Pharmaceuticals, Inc.

ARWR

Same industryBiotechnology

Latest observed price

$68.79

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$82.70

+20.2%

From $68.79 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

Cytokinetics, Incorporated

CYTK

Same industryBiotechnology

Latest observed price

$67.56

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$75.89

+12.3%

From $67.56 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

Krystal Biotech, Inc.

KRYS

Same industryBiotechnology

Latest observed price

$333.85

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$380.85

+14.1%

From $333.85 starting price

Target Sep 21, 2027

Overall Score

Moderate

Forecast basis Sep 21, 2026

Score date Sep 22, 2026

View stock

Vaxcyte, Inc.

PCVX

Same industryBiotechnology

Latest observed price

$58.92

Observed
Sep 21, 2026

12-month forecast

Median (P50)

$68.07

+15.5%

From $58.92 starting price

Target Sep 21, 2027

Overall Score

Unavailable

Forecast basis Sep 21, 2026

Score date —

View stock

12-month forecasts show model median estimates (P50), with changes from each forecast’s starting price. Headline scores describe dated company characteristics; they do not predict future performance.

CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP) stock forecast and scoring

12M forecast summary

Stock scorecard

Company Overview

Similar Stocks

Research snapshot

CRISPR Therapeutics AG research

CRISPR Therapeutics AG (CRSP) stock forecast and scoring

12M forecast summary

Scoring · CRISPR Therapeutics AG (CRSP) stock scorecard

Scoring Breakdown

Growth

Value

Quality

Safety

Momentum

Cash Generation & Balance Strength

Stock scorecard

Company Overview